Comments
Commented by André Will-Laudien on February 15th, 2023 | 11:00 CET
Super Bowl spoils Tesla's bullish mood: Plug Power, First Hydrogen, Nel, ThyssenKrupp - Hydrogen is taking off!
In a true football thriller, the Kansas City Chiefs narrowly defeated their opponents Philadelphia Eagles, just before the end of the game. But it was not just on the field that fans were treated to a spectacle. The commercials during the billion-dollar live broadcast were also eye-catchers, as they are every year. One Super Bowl commercial was a good fight against Tesla's "Full Self Driving" (FSD) mode. Software entrepreneur Dan O'Dowd invested a total of USD 598,000 in his "Dawn Project" campaign. According to its homepage, its goal is to make computers safer for humanity. In the case of Tesla's FSD installations, the campaign sees this as not guaranteed and even judges them to be life-threatening for other road users. From Tesla's side, the content of the commercial was described as "fake". Exciting to see how this case will turn out. We turn away from e-mobility and look at the opportunities for hydrogen.
Read
Commented by André Will-Laudien on February 14th, 2023 | 15:54 CET
Election winners in the fight against cancer! Bayer, Defence Therapeutics, Formycon, Valneva - 300% rises are possible!
In 2021, 18.7 million people received the shocking diagnosis of "cancer". Current trends, unfortunately, suggest that this number will continue to rise in the coming years. Thanks to growing research successes, however, there is hope that biotechnology will make it much more likely that sufferers will survive. It is a matter of developing suitable active substances or launching modern therapies. Recently, mRNA technology has also been making a name for itself in cancer prevention. Innovative biotech companies are back on the radar of risk-conscious investors. Which shares are currently in the spotlight?
Read
Commented by Nico Popp on February 14th, 2023 | 15:49 CET
Takeover fever around biotechs - Bayer's reaction, purchase candidates BioNxt and Morphosys?
Something is happening in the biotech sector: several global players are looking for potential acquisition targets. Above all, pharmaceutical companies focusing on the US are seeing their chances of survival dwindle in light of the Inflation Reduction Act. If drug prices are to fall, new products must be developed or costs cut elsewhere. We take a look at the industry and do a takeover check.
Read
Commented by Fabian Lorenz on February 14th, 2023 | 15:46 CET
Biotech stocks on the verge of a breakout? Evotec, BioNTech, Cardiol Therapeutics
Biotech stocks have largely missed out on the rally of recent weeks. But this could change. Some have interesting chart constellations or a positive news flow. Sooner or later, the stock should then also react with a breakout. After the horror year 2022, Evotec received several positive reports within a few days. The share price has also jumped. At BioNTech, investors are looking away from the COVID-19 vaccine and towards the development pipeline. But, analysts disagree. Are 100% share price gains on the cards? Analysts believe that Cardiol Therapeutics' stock has even more potential than that. Its main product against heart inflammation is already in the Phase II pilot study, and the necessary capital for further development is available. All three shares are recommended as a buy by analysts.
Read
Commented by Stefan Feulner on February 13th, 2023 | 20:09 CET
Rheinmetall, Almonty Industries, Lynas - Rearmament, now!
The decision on the Leopard deliveries to Ukraine has already been made, but now the discussion is turning to the provision of further heavy guns such as the "Panther" super tank developed by Rheinmetall. In addition, the NATO states are discussing the provision of combat aircraft. Once again, an important point is being forgotten. The production of these weapons systems requires critical metals, whose market is primarily dominated by China. The next dependency is thus preprogrammed.
Read
Commented by Armin Schulz on February 13th, 2023 | 20:04 CET
Nel ASA, dynaCERT, Plug Power - Hydrogen as the problem solver in the energy transition
Hydrogen is essential to the energy transition because it can solve many of today's problems. One of these problems is that wind and solar energy are difficult to plan. Since they produce irregularly, the surplus on sunny days or windy days must be stored. This is how green hydrogen is produced, which can solve the problem of fossil fuels in the field of mobility solutions. Current electric solutions are not yet convincing, especially for freight transport, but this is where most CO2 is produced. With hydrogen, vehicles have more range and, most importantly, shorter charging times. We look at three companies that have built their business using hydrogen.
Read
Commented by Juliane Zielonka on February 10th, 2023 | 18:56 CET
Defence Therapeutics, Bayer, BioNTech - US investors love biotech stocks
US investors love biotech companies. So it is thanks to pressure from investor Jeff Ubben that Bayer AG's leadership is changing a year earlier than planned. Shareholders welcome the decision, with Bayer's share price rising a whopping 5% this week. The fight against cancer is the mission of the Canadian company Defence Therapeutics. They have taken another critical step forward in the pipeline to bring their cancer therapy to solid tumors. BioNTech co-founder Ugur Sahin is also showing commitment. The Turkish-born physician actively supports the crisis regions of the earthquakes in his home country and Syria. Find out how this relates to the Group's profits here.
Read
Commented by Armin Schulz on February 10th, 2023 | 12:40 CET
Defense Metals, Rheinmetall, Encavis - New technologies cannot do without this critical raw material
What do metal alloys, magnets, phosphors, ceramics, glass, catalysts and chemical processes need to function well? Rare earths - a critical raw material that is primarily processed in China. Without this raw material, there are no smartphones, computers, wind turbines or electric vehicles. There have been tensions between China and the United States for some time. If these tensions escalate and China stops its rare earth supplies, the Western world will have a problem. As demand for rare earths continues to rise, it is important to ensure sufficient supplies to meet the growing demands of the technology industry.
Read
Commented by Nico Popp on February 10th, 2023 | 12:37 CET
Real estate crash - alternatives to housing: Commerzbank, Alpina Holdings, Hypoport
"Emergency braking" and "The worst is yet to come!" - these or similar are comments on the German real estate market. Although housing is scarce, hardly anyone can afford it. Residential real estate sales are at rock bottom, and new construction plans are being cancelled by the dozen. Are real estate investments at the end? We show flexible alternatives on the stock market without huge purchase costs.
Read
Commented by Nico Popp on February 9th, 2023 | 19:54 CET
Comeback opportunity or a complete washout? These facts decide: Deutsche Bank, K+S, Tocvan Ventures
Various sectors have enjoyed a boom in recent months. Commodity companies benefited from rising prices, and banks from higher interest rates. But the trees do not grow to the sky even for stocks favoured by the market. Every trend comes to an end. Where investors can believe in comebacks and where uneasiness could threaten - we take a close look for you!
Read